Adam Scott Levy
Known title: CFO, Chief Bus. Off. and Secy.CIK: 0001693134
Adam Scott Levy's purchase track record
Adam Scott Levy has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/14/2023 | MLYS | $100K | -14.2% | -30.8% | +7.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| MLYS | ▲ Buy | Grant | 39,900 | $0 | 2/19/2026 | View on chart |
| MLYS | ▼ Sell | Open Market | 10,758 | $346K | 1/12/2026 | View on chart |
| MLYS | ▼ Sell | Open Market | 32,718 | $1.5M | 11/11/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 38,900 | $1.8M | 11/11/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 8,456 | $382K | 11/11/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 4,142 | $180K | 11/11/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 8,485 | $359K | 11/11/2025 | View on chart |
| MLYS | ▲ Buy | Option Exercise | 20,547 | $210K | 11/11/2025 | View on chart |
| MLYS | ▲ Buy | Option Exercise | 34,414 | $551K | 11/11/2025 | View on chart |
| MLYS | ▲ Buy | Option Exercise | 44,079 | $628K | 11/11/2025 | View on chart |
| MLYS | ▲ Buy | Option Exercise | 6,613 | $102K | 11/11/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 1,015 | $43K | 11/11/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 11,295 | $473K | 11/11/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 1,561 | $67K | 11/11/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 12,952 | $539K | 11/11/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 7,366 | $309K | 10/13/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 3,392 | $143K | 10/13/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 51,500 | $757K | 7/30/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 8,425 | $127K | 7/30/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 807 | $11K | 7/29/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 12,946 | $182K | 7/28/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 10,758 | $155K | 7/11/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 10,757 | $130K | 4/11/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 10,657 | $97K | 1/13/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 100 | $963 | 1/13/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 10,757 | $146K | 10/11/2024 | View on chart |
| MLYS | ▼ Sell | Open Market | 10,757 | $141K | 7/11/2024 | View on chart |
| MLYS | ▼ Sell | Open Market | 96,815 | $1.3M | 6/11/2024 | View on chart |
| MLYS | ▲ Buy | Open Market | 6,250 | $100K | 2/14/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Mineralys Presents Phase 3 Data, Receives Mixed Analyst Views
Mineralys Therapeutics presented new data from its pivotal Phase 3 Launch-HTN study at the American Heart Association Hypertension Scientific Sessions 2026. Following this update, UBS initiated coverage with a Neutral rating and a $29 price target, while HC Wainwright reiterated a Buy rating with a $56 target. The stock is currently trading near its support level, reflecting the divided analyst opinions on the company's outlook.
Mineralys Presents Phase 3 Data, Receives Mixed Analyst Views. Mineralys Therapeutics presented new data from its pivotal Phase 3 Launch-HTN study at the American Heart Association Hypertension Scientific Sessions 2026. Following this update, UBS initiated coverage with a Neutral rating and a $29 price target, while HC Wainwright reiterated a Buy rating with a $56 target. The stock is currently trading near its support level, reflecting the divided analyst opinions on the company's outlook.